New autoimmune drug VIS171 passes first safety check in humans

NCT ID NCT05418101

First seen Apr 22, 2026 · Last updated May 16, 2026 · Updated 6 times

Summary

This early-stage study tested a new drug called VIS171 in 61 people, first in healthy volunteers and then in patients with autoimmune diseases. The main goal was to check safety and how the body processes the drug. Results will help decide if further testing is warranted.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ambulatory for Specialized Medical Help - skin and venereal diseases

    Sofia, 1407, Bulgaria

  • Clinical republican Hospital

    Chisinau, MD 2025, Moldova

  • Comac Medical Ltd

    Sofia, 1612, Bulgaria

  • Diagnostic and Consultative Center Convex EOOD

    Sofia, 1680, Bulgaria

  • MBAL Sveta Sofia

    Sofia, 1618, Bulgaria

  • New Zealand Clinical Research

    Christchurch, 8011, New Zealand

  • Radboud University Medical Center

    Gelderland, 6525, Netherlands

  • UMHAT

    Plovdiv, 4002, Bulgaria

  • Universitaetsklinikum Bonn AöR

    Bonn, 53127, Germany

  • Universitätsmedizin der Johannes-Gutenberg-Universität Mainz

    Rheinland-Pfalz, 55131, Germany

Conditions

Explore the condition pages connected to this study.